dr. mcdermott on single-agent versus combination immunotherapy in rcc
Published 5 years ago • 109 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:08
mcdermott: immunotherapy agents in renal cell carcinoma
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:02
dr. gupta discusses combination immunotherapy in rcc
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
0:59
dr. alva on tki monotherapy and combinations for rcc
-
1:27
dr. mcdermott on vegf/pd-1 inhibition in rcc
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc